FUNDING THE BEST BRAINS TO BEAT BRAIN CANCER
Dr Charlie Teo AM, Professor of Neurosurgery
Director and Founder, Charlie Teo Foundation
FUNDER PROFILE
Filmed in Sydney, Australia | December 2024
The Charlie Teo Foundation is dedicated to funding and advancing research into brain cancer, with a particular focus on developing more effective treatments and finding a cure for this devastating disease. The foundation’s mission includes:
- Supporting cutting-edge research: The foundation funds innovative research into brain cancer, aiming to discover new therapies, improve outcomes, and ultimately find a cure.
- Raising awareness: The foundation works to increase public awareness about brain cancer, its impact on patients and families, and the need for more research and funding in this field.
- Helping patients: In addition to supporting research, the foundation assists individuals and families affected by brain cancer by providing information, resources, and support.
- Advocating for change: It strives to drive systemic change in how brain cancer is researched and treated, challenging the status quo and encouraging collaboration and innovation within the medical community.
Dr. Charlie Teo AM as the Founder and Director of the Charlie Teo Foundation, has for over 30 years been instrumental in the development, dissemination and acceptance of the concept of keyhole minimally invasive techniques in neurosurgery. Dr Teo ran a fellowship program that attracts over 600 applicants yearly and has trained many of the world’s leading figures in neurosurgery. He has trained at distinguished centres such as the Barrow Neurological Institute, Johns Hopkins University, Duke University, Stanford University, Vanderbilt University and Harvard University.
Initially focused on Australia, Dr Teo recognised a pressing need to raise funds for brain cancer research from a young age. To address this, he founded the Charlie Teo Foundation in 2017, which aims to increase awareness and funding for brain cancer research.
Brain cancer significantly impacts society, being the leading cause of years of life lost. Despite its high incidence, particularly among young adults and children, it remains one of the least funded cancers. The foundation operates with low overhead costs and focuses on supporting disruptive researchers who think outside the box.
Since its inception, the foundation has committed nearly $15 million to brain cancer research, funding notable projects in Australia and the United States. These projects explore innovative approaches to understand and treat brain cancer more effectively, with a focus on translating findings from animal studies to human applications. Charlie’s dedication to finding solutions for this devastating disease remains unwavering as he travels frequently to collaborate with global researchers.
-
Muscle Cell Communication and Repair
Dr. William Roman is a Group Leader at the Australian Regenerative Medicine Institute (ARMI) at Monash University. He obtained his PhD from Paris Descartes University and Freie University of Berlin, focusing on nuclear positioning during skeletal muscle development. Dr. Roman’s research journey has taken him across the globe, including postdoctoral work in Barcelona, tissue engineering in Lisbon, and a brief stint at Stanford University.
At ARMI, Dr. Roman leads innovative research on intercellular communication within muscle organs. His work involves growing human muscles on chips to understand how skeletal muscle cells interact with neurons and tendons. This research aims to develop better models for studying muscle diseases, drug screening, and even applications in cellular agriculture and biorobotics.
-
Precision and personalised nutrition
Laureate Professor Clare Collins is helping people access effective medical nutrition therapies that significantly reduce their risk of chronic disease. She and her team are developing innovative technologies, including apps and online programmes.
-
Investigating invasive lobular carcinoma and metaplastic breast cancer sub-types
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
